The methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth

Oncogene

Volumn 25, Issue 9, 2006, Pages 1358-1366

  Bernard, D ^a,f   Gil, J ^b   Dumont, P ^c   Rizzo, S ^d   Monte D ^c   Quatannens, B ^c   Hudson, D ^d   Visakorpi, T ^e   Fuks, F ^a   De Launoit, Y ^a,c  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIV LILLE   (France)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cancer; Epigenetic; Growth; Methyl CpG binding protein; Prostate

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; METHYL CPG BINDING PROTEIN 2; MYC PROTEIN; PROTEIN P53; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENIC ACTIVITY; CARCINOGENICITY; CONTROLLED STUDY; CPG ISLAND; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION;

ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; MALE; METHYL-CPG-BINDING PROTEIN 2; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 33644767915     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209179     Document Type: Article

References (50)

1. Abate-Shen C, Shen MM. (2000). Genes Dev 14: 2410-2434.
2. Abrahamsson PA, Falkmer S, Fait K, Grimelius L. (1989). Pathol Res Pract 185: 373-380.
3. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. (2000). Prostate 42: 274-279.
4. Baylin SB, Herman JG. (2000). Trends Genet 16: 168-174.
5. Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH. (2003). J Clin Invest 112: 1724-1731.
6. Bernard D, Quatannens B, Begue A, Vandenbunder B, Abbadie C. (2001). Cancer Res 61: 2656-2664.
7. Burgers WA, Fuks F, Kouzarides T. (2002). Trends Genet 18: 275-277.
8. Carlson CA, Ethier SP. (2000). Radiat Res 154: 590-599.
9. Carroll AG, Voeller HJ, Sugars L, Gelmann EP. (1993). Prostate 23: 123-134.
10. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004). Nat Med 10: 33-39.
11. Cheng JC, Yoo CB, Weisenberger DJ, Chuang J, Wozniak C, Liang G et al. (2004). Cancer Cell 6: 151-158.
12. Cohen RJ, Glezerson G, Haffejee Z, Afrika D. (1990). Br J Urol 66: 405-410.
13. Denmeade SR, Isaacs JT. (2002). Nat Rev Cancer 2: 389-396.
14. Dobosy JR, Selker EU. (2001). Cell Mol Life Sci 58: 721-727.
15. Feldman BJ, Feldman D. (2001). Nat Rev Cancer 1: 34-45.
16. Fojo T, Bates S. (2003). Oncogens 22: 7512-7523.
17. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. (2003). J Biol Chem 278: 4035-4040.
18. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R et al. (2004). Nat Rev Cancer 4: 177-183.
19. Goffin J, Eisenhauer E. (2002). Ann Oncol 13: 1699-1716.
20. Hanahan D, Weinberg RA. (2000). Cell 100: 57-70.
21. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al. (1998). Science 281: 1509-1512.
22. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. (2004). Eur Urol 45: 586-592.
23. Hudson DL, Masters JR. (2003). Methods Mol Med 81: 59-67.
24. Jones PA. (2002). Oncogene 21: 5358-5360.
25. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. (1998). Mol Cell 1: 543-551.
26. Kellen JA. (1994). Anticancer Res 14: 433-435.
27. Kimura H, Shiota K. (2003). J Biol Chem 278: 4806-4812.
28. Kongkanuntn R, Bubb VJ, Sansom OJ, Wyllie AH, Harrison DJ, Clarke AR. (1999). Oncogene 18: 7219-7225.
29. Kudo S, Nomura Y, Segawa M, Fujita N, Nakao M, Dragich J et al. (2001). Brain Dev 23(Suppl 1): S165-S173.
30. Li L-C, Okino ST, Dahiya R. (2004). Biochim Biophys Acta (BBA) Rev Cancer 1704: 87-102.
31. Lund AH, van Lohuizen M. (2004). Cur Opin Cell Biol 16: 239-246.
32. Miyoshi Y, Uemura H, Kitami K, Satomi Y, Kubota Y, Hosaka M. (2001). BJU Int 88: 982-983.
33. Nan X, Cross S, Bird A. (1998a). Novartis Found Symp 214: 6-16; discussion 16-21, 46-50.
34. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN et al. (1998b). Nature 393: 386-389.
35. Nelson WG, De Marzo AM, Isaacs WB. (2003). N Engl J Med 349: 366-381.
36. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H et al. (1999). Nat Genet 23: 58-61.
37. Porkka KP, Visakorpi T. (2004). Eur Urol 45: 683-691.
38. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. (2003). Nat Genet 34: 145-147.
39. Sears RC. (2004). Cell Cycle 3: 1133-1137.
40. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M et al. (2004). Cancer Res 64: 9209-9216.
41. Taplin ME, Balk SP. (2004). J Cell Biochem 91: 483-490.
42. Tetu B, Ro JY, Ayala AG, Johnson DE, Logothetis CJ, Ordonez NG. (1987). Cancer 59: 1803-1809.
43. Valkov NI, Sullivan DM. (2003). Drug Resistance Updates 6: 27-39.
44. Visakorpi T. (2003). Urology 62: 3-10.
45. Wang J, Xie LY, Allan S, Beach D, Hannon GJ. (1998). Genes Dev 12: 1769-1774.
46. Wolf DA, Schulz P, Fittler F. (1992). Mol Endocrinol 6: 753-762.
47. Wright ME, Tsai MJ, Aebersold R. (2003). Mol Endocrinol 17: 1726-1737.
48. Yeap BB, Krueger RG, Leedman PJ. (1999). Endocrinology 140: 3282-3291.
49. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S. (2001). Cancer Chemother Pharmacol 48(Suppl 1): S20-S26.
50. Zhu WG, Otterson GA. (2003). Curr Med Chem Anti-Canc Agents 3: 187-199.